Focal segmental glomerulosclerosis (FSGS), a rare and aggressive kidney disease characterized by scarring of the glomeruli, has no known cure but treatment options are expanding.
The progressive disease, which is estimated to affect more than 40,000 people in the U.S., causes chronic proteinuria and irreversible damage, frequently leading to kidney failure.
"This is a difficult diagnosis to treat and one that is both frustrating for patient and nephrologists," Kristin Meliambro, MD, of the Icahn School of Medicine at Mount Sinai in New York City, told MedPage Today.
One of the primary goals of treatment is to lower proteinuria, said Abbal Koirala, MD, of the Johns Hopkins School of Medicine in Baltimore. "Ongoing persistent proteinuria is a risk factor for chronic kidney disease progression and progression to end-stage renal disease," he told MedPage Today.
Current Treatments
